Concepts (154)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neurosecretory Systems | 1 | 2019 | 238 | 0.650 |
Why?
|
Glioma | 2 | 2020 | 3292 | 0.550 |
Why?
|
Patient Care | 1 | 2021 | 610 | 0.540 |
Why?
|
Neuroendocrine Tumors | 1 | 2020 | 534 | 0.540 |
Why?
|
Microtubule-Associated Proteins | 1 | 2020 | 1108 | 0.530 |
Why?
|
Neuropeptides | 1 | 2020 | 929 | 0.520 |
Why?
|
Lassa Fever | 4 | 2018 | 97 | 0.520 |
Why?
|
Rectal Neoplasms | 1 | 2021 | 1117 | 0.450 |
Why?
|
Radiation Injuries | 1 | 2019 | 1228 | 0.430 |
Why?
|
Lassa virus | 3 | 2015 | 92 | 0.370 |
Why?
|
Brain Neoplasms | 2 | 2020 | 8776 | 0.340 |
Why?
|
Prostatic Neoplasms | 2 | 2021 | 10525 | 0.330 |
Why?
|
Neoplasm Proteins | 1 | 2020 | 3773 | 0.320 |
Why?
|
Orthopedics | 2 | 2011 | 805 | 0.280 |
Why?
|
Musculoskeletal Diseases | 1 | 2011 | 545 | 0.270 |
Why?
|
Educational Measurement | 1 | 2011 | 1271 | 0.240 |
Why?
|
Teaching | 1 | 2011 | 1185 | 0.230 |
Why?
|
Adenocarcinoma | 1 | 2020 | 6338 | 0.230 |
Why?
|
Education, Medical, Undergraduate | 1 | 2011 | 988 | 0.220 |
Why?
|
Pandemics | 1 | 2021 | 7089 | 0.210 |
Why?
|
Curriculum | 1 | 2011 | 3329 | 0.160 |
Why?
|
Cardiology Service, Hospital | 1 | 2019 | 253 | 0.160 |
Why?
|
Standard of Care | 1 | 2021 | 497 | 0.160 |
Why?
|
Comparative Effectiveness Research | 1 | 2021 | 672 | 0.140 |
Why?
|
Confidence Intervals | 1 | 2020 | 2920 | 0.130 |
Why?
|
Statistics, Nonparametric | 1 | 2020 | 2945 | 0.130 |
Why?
|
Breast Neoplasms | 1 | 2021 | 19800 | 0.120 |
Why?
|
Infection Control | 1 | 2021 | 959 | 0.120 |
Why?
|
Prostate | 1 | 2020 | 1564 | 0.110 |
Why?
|
Patient Admission | 1 | 2019 | 1398 | 0.110 |
Why?
|
Genome, Viral | 1 | 2015 | 676 | 0.110 |
Why?
|
Visual Cortex | 1 | 2019 | 1137 | 0.100 |
Why?
|
N-Acetylglucosaminyltransferases | 1 | 2012 | 181 | 0.100 |
Why?
|
Selection, Genetic | 2 | 2013 | 882 | 0.100 |
Why?
|
Genetic Techniques | 1 | 2013 | 440 | 0.100 |
Why?
|
Linear Models | 1 | 2020 | 5986 | 0.090 |
Why?
|
Genome, Human | 2 | 2013 | 4493 | 0.090 |
Why?
|
Academic Medical Centers | 1 | 2019 | 2779 | 0.090 |
Why?
|
Single-Cell Analysis | 1 | 2019 | 2159 | 0.090 |
Why?
|
Bone Plates | 1 | 2011 | 428 | 0.090 |
Why?
|
Risk | 1 | 2021 | 9641 | 0.090 |
Why?
|
Radiology | 1 | 2021 | 1931 | 0.080 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2021 | 9488 | 0.080 |
Why?
|
Interleukins | 1 | 2012 | 799 | 0.080 |
Why?
|
RNA, Viral | 1 | 2015 | 2847 | 0.080 |
Why?
|
Cholera | 1 | 2013 | 750 | 0.080 |
Why?
|
Proportional Hazards Models | 1 | 2021 | 12292 | 0.070 |
Why?
|
Radius Fractures | 1 | 2011 | 472 | 0.070 |
Why?
|
Fracture Fixation, Internal | 1 | 2011 | 827 | 0.070 |
Why?
|
Clinical Competence | 2 | 2011 | 4615 | 0.070 |
Why?
|
Prosthesis Design | 1 | 2011 | 2146 | 0.060 |
Why?
|
Healthcare Disparities | 1 | 2019 | 2996 | 0.060 |
Why?
|
African Americans | 1 | 2019 | 5118 | 0.060 |
Why?
|
Nigeria | 2 | 2018 | 683 | 0.060 |
Why?
|
Africa, Western | 2 | 2015 | 152 | 0.060 |
Why?
|
Schools, Medical | 1 | 2011 | 871 | 0.060 |
Why?
|
Risk Assessment | 3 | 2021 | 23284 | 0.060 |
Why?
|
Algorithms | 2 | 2021 | 13647 | 0.060 |
Why?
|
Humans | 16 | 2021 | 708843 | 0.060 |
Why?
|
Evolution, Molecular | 1 | 2012 | 1959 | 0.060 |
Why?
|
Gene Expression Profiling | 1 | 2019 | 9556 | 0.060 |
Why?
|
Fellowships and Scholarships | 1 | 2010 | 978 | 0.060 |
Why?
|
Health Services Accessibility | 1 | 2019 | 4988 | 0.060 |
Why?
|
Disease Progression | 1 | 2019 | 13298 | 0.060 |
Why?
|
Male | 8 | 2021 | 349524 | 0.050 |
Why?
|
Prospective Studies | 2 | 2019 | 50597 | 0.050 |
Why?
|
Leadership | 1 | 2010 | 1325 | 0.050 |
Why?
|
Cryotherapy | 1 | 2021 | 157 | 0.050 |
Why?
|
Adult | 6 | 2020 | 211041 | 0.050 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2021 | 632 | 0.040 |
Why?
|
Quality of Life | 1 | 2019 | 11594 | 0.040 |
Why?
|
Students, Medical | 1 | 2011 | 1740 | 0.040 |
Why?
|
Female | 7 | 2021 | 375205 | 0.040 |
Why?
|
Heart Failure | 1 | 2019 | 10040 | 0.040 |
Why?
|
Murinae | 1 | 2015 | 19 | 0.040 |
Why?
|
Disease Reservoirs | 1 | 2015 | 141 | 0.030 |
Why?
|
Zoonoses | 1 | 2015 | 146 | 0.030 |
Why?
|
NF-kappa B | 2 | 2013 | 2563 | 0.030 |
Why?
|
Sierra Leone | 1 | 2014 | 146 | 0.030 |
Why?
|
Genome-Wide Association Study | 1 | 2013 | 11738 | 0.030 |
Why?
|
Organoids | 1 | 2019 | 634 | 0.030 |
Why?
|
Rivers | 1 | 2013 | 56 | 0.030 |
Why?
|
Toll-Like Receptor 5 | 1 | 2013 | 39 | 0.030 |
Why?
|
Ebolavirus | 1 | 2015 | 244 | 0.030 |
Why?
|
Brain | 1 | 2019 | 24969 | 0.030 |
Why?
|
Phylogeography | 1 | 2012 | 85 | 0.030 |
Why?
|
Flagellin | 1 | 2013 | 129 | 0.030 |
Why?
|
Ribavirin | 1 | 2014 | 396 | 0.030 |
Why?
|
Regulatory Elements, Transcriptional | 1 | 2013 | 185 | 0.030 |
Why?
|
Mutation | 2 | 2015 | 29262 | 0.030 |
Why?
|
Hemorrhagic Fever, Ebola | 1 | 2015 | 390 | 0.020 |
Why?
|
Immunoassay | 1 | 2014 | 766 | 0.020 |
Why?
|
Middle Aged | 3 | 2019 | 213752 | 0.020 |
Why?
|
Biological Evolution | 1 | 2015 | 1084 | 0.020 |
Why?
|
Antigens, Viral | 1 | 2014 | 1153 | 0.020 |
Why?
|
Wrist Injuries | 1 | 2011 | 194 | 0.020 |
Why?
|
Inflammasomes | 1 | 2013 | 420 | 0.020 |
Why?
|
Models, Genetic | 1 | 2019 | 3539 | 0.020 |
Why?
|
Fracture Healing | 1 | 2011 | 405 | 0.020 |
Why?
|
Postoperative Complications | 1 | 2011 | 15053 | 0.020 |
Why?
|
Inpatients | 1 | 2019 | 2207 | 0.020 |
Why?
|
Seasons | 1 | 2014 | 1433 | 0.020 |
Why?
|
Injury Severity Score | 1 | 2011 | 987 | 0.020 |
Why?
|
Health Status Disparities | 1 | 2019 | 1711 | 0.020 |
Why?
|
Viral Proteins | 1 | 2015 | 1967 | 0.020 |
Why?
|
Glycoproteins | 1 | 2015 | 2309 | 0.020 |
Why?
|
Vibrio cholerae | 1 | 2013 | 812 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2019 | 3708 | 0.020 |
Why?
|
Boston | 1 | 2019 | 9402 | 0.020 |
Why?
|
Immunotherapy | 1 | 2021 | 4057 | 0.020 |
Why?
|
Treatment Outcome | 3 | 2019 | 61932 | 0.020 |
Why?
|
Sex Distribution | 1 | 2011 | 2328 | 0.020 |
Why?
|
Computer Simulation | 1 | 2019 | 6048 | 0.020 |
Why?
|
Patient Readmission | 1 | 2019 | 2952 | 0.020 |
Why?
|
Age Distribution | 1 | 2011 | 2876 | 0.020 |
Why?
|
Quantitative Trait Loci | 1 | 2013 | 1976 | 0.020 |
Why?
|
Range of Motion, Articular | 1 | 2011 | 1519 | 0.020 |
Why?
|
Retrospective Studies | 3 | 2019 | 71483 | 0.020 |
Why?
|
Incidence | 2 | 2014 | 20320 | 0.020 |
Why?
|
Joint Instability | 1 | 2011 | 748 | 0.020 |
Why?
|
Program Development | 1 | 2010 | 1328 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2018 | 12447 | 0.020 |
Why?
|
Reference Values | 1 | 2010 | 5041 | 0.010 |
Why?
|
Antibodies, Viral | 1 | 2014 | 2930 | 0.010 |
Why?
|
Logistic Models | 1 | 2018 | 13468 | 0.010 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2014 | 1999 | 0.010 |
Why?
|
Cohort Studies | 2 | 2018 | 39292 | 0.010 |
Why?
|
Bacteria | 1 | 2013 | 2040 | 0.010 |
Why?
|
Program Evaluation | 1 | 2010 | 2524 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2019 | 19423 | 0.010 |
Why?
|
Pain Measurement | 1 | 2011 | 3510 | 0.010 |
Why?
|
Survival Analysis | 1 | 2014 | 10507 | 0.010 |
Why?
|
Aged, 80 and over | 2 | 2019 | 58184 | 0.010 |
Why?
|
Radiography | 1 | 2011 | 6989 | 0.010 |
Why?
|
Animals | 3 | 2019 | 170486 | 0.010 |
Why?
|
Genetic Variation | 1 | 2015 | 6666 | 0.010 |
Why?
|
Societies, Medical | 1 | 2010 | 3776 | 0.010 |
Why?
|
Education, Medical, Graduate | 1 | 2010 | 2176 | 0.010 |
Why?
|
Time Factors | 1 | 2019 | 41038 | 0.010 |
Why?
|
Age Factors | 1 | 2014 | 18712 | 0.010 |
Why?
|
Young Adult | 2 | 2014 | 55940 | 0.010 |
Why?
|
Aged | 2 | 2019 | 161488 | 0.010 |
Why?
|
Pregnancy | 1 | 2014 | 26832 | 0.010 |
Why?
|
Risk Factors | 1 | 2019 | 69553 | 0.010 |
Why?
|
Mice | 1 | 2019 | 80876 | 0.010 |
Why?
|
Infant | 1 | 2014 | 34261 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2013 | 17218 | 0.010 |
Why?
|
Child, Preschool | 1 | 2014 | 41081 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2010 | 23020 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2011 | 39038 | 0.010 |
Why?
|
Signal Transduction | 1 | 2013 | 23950 | 0.010 |
Why?
|
Child | 1 | 2014 | 73636 | 0.000 |
Why?
|
Adolescent | 1 | 2014 | 84718 | 0.000 |
Why?
|
United States | 1 | 2010 | 67165 | 0.000 |
Why?
|
Concepts
(154)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(98)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_